12.2 C
New York
Monday, June 5, 2023

Intellia Therapeutics Inc. (NASDAQ: NTLA) May Be Attracting Institutional Investments

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Intellia Therapeutics Inc. (NTLA) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.10, or -0.26%, to $38.48. The Intellia Therapeutics Inc. has recorded 75,639 volume in the after hours trading session. Recently, Yahoo Finance discussed the stock, revealing that Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) Priorities.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.


Stocks Info

Intellia Therapeutics Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $38.58 and fluctuated between $39.72 as its day high and $37.08 as its day low. The current market capitalization of Intellia Therapeutics Inc. is $3.26B. A total of 1.03 million shares were traded on the day, compared to an average of 1.07M shares.

Insider Activity

Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, NTLA has seen 10 BUY and 1 SELL insider trades, representing the acquisition of 280,654 and the disposition of 1,088 shares. Over the last 12 months, there were 22 BUYs and 12 SELLs from insiders. Insiders purchased 336,644 shares during that period but sold 22,578.

In the most recent transaction, Sepp-Lorenzino Laura sold 2,330 shares of NTLA for 38.48 per share on Jan 05. After the transaction, the EVP, Chief Scientific Officer now owns 17,629 company shares. In a previous transaction on Jan 04, LEONARD JOHN M sold 6,673 shares at 37.21 per share. NTLA shares that President and CEO owns now total 766,825.

Among the insiders who sold shares, Lebwohl David disposed of 2,574 shares on Jan 04 at a per-share price of $37.21. This resulted in the EVP, Chief Medical Officer holding 25,687 shares of NTLA after the transaction. In another insider transaction, Sepp-Lorenzino Laura sold 2,508 shares at $37.21 per share on Jan 04. Company shares held by the EVP, Chief Scientific Officer now total 19,959.

Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for NTLA in the last 3 months, the mean price target is $92.89 with high estimates of $168.00 and low estimates of $39.00. In terms of 52-week highs and lows, NTLA has a high of $76.45 and a low of $32.44.

As of this writing, NTLA has an earnings estimate of $-1.4 per share for the current quarter. EPS was calculated based on a consensus of 25 estimates, with a high estimate of $-1.17 per share and a lower estimate of $-1.7. The company reported an EPS of $-1.49 in the last quarter, which was -16.40% lower than expectations of $-1.28.

Balance Sheet Annually/Quarterly

A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. NTLA’s latest balance sheet shows that the firm has $1.09B in Cash & Short Term Investments as of fiscal 2021. There were $74.02M in debt and $125.83M in liabilities at the time. Its Book Value Per Share was $15.21, while its Total Shareholder’s Equity was $1.04B.

Analysts Opinion

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 29 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for NTLA is Sell with a score of 4.72. A total of 22 analysts rated the stock as Buy while 3 rated it as Overweight while 4 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles